US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,390.06

+7.470.54%

Number of Gainers:2

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,390.13

Open:1,383.64

Low:1,382.49

Close:1,382.59

Loading ...

Gilead: Both Applications of Lenacapavir for Hiv Prevention Will Be Assessed in Parallel Under Accelerated Assessment Review Timeline

THOMSON REUTERS

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

bluebird bio Inc : JP Morgan Raises to Neutral From Underweight

THOMSON REUTERS

Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks

Novartis AG (NVS): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

BofA moves to No Rating on Bluebird Bio after deal announcement

Top Midday Decliners

MT Newswires Live

Bluebird bio's CVR Payout Seen as a Stretch -- Market Talk

Bluebird Bio trading resumes

Bluebird Bio trading halted, volatility trading pause

Bluebird Bio downgraded to Neutral from Outperform at Baird

BRIEF-Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK Capital

What's Going On With Gene Therapy Company Bluebird Bio Stock Today?

BUZZ-Bluebird bio falls on discounted take private deal with Carlyle, SK Capital

bluebird bio Shares Down 40% Premarket; Co to Be Acquired by Carlyle and SK Capital

THOMSON REUTERS

Bluebird bio to Be Acquired by Carlyle Group, SK Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4578/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1390.0568,"timestamp":1741278203229,"preClose":1382.588,"halted":0,"volume":2481628,"delay":0,"changeRate":0.005402,"change":7.46875,"pbRate":5.765336,"amount":278317430.633896,"amplitude":0.005526,"prevYearClose":1164.883,"fiveDayClose":1344.2782,"twentyDayClose":1292.9265,"turnoverRate":0.000791,"marketCap":366705420764,"floatMarketCap":356025191840,"peRate":30.124118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1390.1277,"amplitude":0.005526,"preClose":1382.588,"low":1382.4882,"pbRate":"5.765336","latestPrice":1390.0568,"volume":2481480,"delay":0,"open":1383.6362,"prevYearClose":1164.883,"prevWeekClose":1356.2184,"prevMonthClose":1356.2184,"prevQuarterClose":1164.883,"fiveDayClose":1344.2782,"twentyDayClose":1292.9265,"sixtyDayClose":1204.1672,"secType":"PLATE","market":"US","turnoverRate":0.000791,"peRate":30.124118,"marketCap":366705420764,"floatMarketCap":356025191840,"timestamp":1741278202151,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":2,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513151729","title":"Gilead:  Both Applications of Lenacapavir for Hiv Prevention Will Be Assessed in Parallel Under Accelerated Assessment Review Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2513151729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513151729?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUABNG9BW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4550","BK4588","BK4578","LU0109394709.USD","LU1839511570.USD","LU0234570918.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU2468319806.SGD","BK4583","LU2089984988.USD","GILD","BK4566","IE00B19Z3B42.SGD","IE0002270589.USD","LU1066053197.SGD","LU0320765992.SGD","LU2087621335.USD","IE00B19Z3581.USD","IE00B3T34201.USD","BK4532","BK4568","LU1585245621.USD","LU0889565916.HKD","LU1430594728.SGD","IE00BSNM7G36.USD","BK4585","LU1571399168.USD","BK4139","IE00BKVL7J92.USD","LU1066051498.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2513210957","title":"European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2513210957","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513210957?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"– One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries –。The EMA validation follows the announcement last week that the U.S. Food and Drug and Administration  accepted Gilead’s New Drug Applications  for lenacapavir for PrEP and will assess them under priority review.The EMA applications are supported by data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by Gilead. In PURPOSE 1 , data showed twice-yearly lenacapavir demonstrated zero infections in the lenacapavir group and 100% risk reduction and superiority compared to background HIV incidence  for the investigational use of HIV prevention in cisgender women. In PURPOSE 2 , there were two HIV infections in the lenacapavir group, demonstrating 99.9% of participants in the lenacapavir group did not acquire HIV infection, a 96% risk reduction in HIV infections, and superiority compared to bHIV among a broad and geographically diverse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-validates-gilead-133000551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","BK4139","BK4566","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1066051498.USD","BK4532","MAA","BK4550","LU2089984988.USD","LU0889565916.HKD","BK4588","LU1066053197.SGD","LU1430594728.SGD","LU2468319806.SGD","CHMP","BK4156","BK4578","BK4585","IE00B3T34201.USD","LU2087621335.USD","GILD","LU0109394709.USD","LU0058720904.USD","BK4215","IE00BKVL7J92.USD","LU1571399168.USD","IE0002270589.USD","LU1839511570.USD","LU1585245621.USD","LU0320765992.SGD","MDCO","BK4583","BK4568","BK4087","LU0289739699.SGD","IE00B7SZLL34.SGD","LU0234570918.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2513792033","title":"bluebird bio Inc : JP Morgan Raises to Neutral From Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2513792033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513792033?lang=en_us&edition=fundamental","pubTime":"2025-02-24 13:23","pubTimestamp":1740374629,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF0A2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4578","BK4139","BLUE"],"gpt_icon":0},{"id":"2513549527","title":"Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2513549527","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513549527?lang=en_us&edition=fundamental","pubTime":"2025-02-24 02:14","pubTimestamp":1740334499,"startTime":"0","endTime":"0","summary":"We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Gilead Sciences, Inc.  stands against other Renaissance Technologies portfolio's top stock picks.The American quant hedge fundRenaissance Technologiesis known for using statistical and mathematical tools to drive its investment programs. It was founded in 1982 by Jim Simons, a mathematician who worked as a code breaker for the US National Security Agency during the Cold War. As of December 31, Renaissance Technologies had a portfolio valued at over $67.5 billion.READ ALSO:Cathie Wood’s Stock Portfolio: 2025 Stock PicksandJim Cramer’s February Portfolio: Top 10 Stocks.We scanned Renaissance Technologies’ 13F portfolio, as of December 31, 2024. From there, we picked the top 10 stocks according to their stake value and ranked them in ascending order.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-among-181459552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","LU0889565916.HKD","LU1066051498.USD","MNQmain","USJW.SI","QID","QLD","BK4578","IE00BKVL7J92.USD","IE00B3T34201.USD","BK4550","IE00B19Z3581.USD","BK4585","BK4583","LU2468319806.SGD","GILD","TQQQ","BK4532","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0320765992.SGD","LU1839511570.USD","LU0234570918.USD","PBC","PSQ","USAW.SI",".IXIC","TSYW.SI","LU0058720904.USD","LU1430594728.SGD","BK4566","SQQQ","IE00BZ1G4Q59.USD","LU1571399168.USD","NVIW.SI","LU2087621335.USD","IE00B7SZLL34.SGD","BK4588","IE00BSNM7G36.USD","BK4139","LU0109394709.USD","LU1066053197.SGD","LU1585245621.USD","NQmain","IE0002270589.USD","LU2089984988.USD"],"gpt_icon":1},{"id":"2513784246","title":"Novartis AG (NVS): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2513784246","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513784246?lang=en_us&edition=fundamental","pubTime":"2025-02-23 12:17","pubTimestamp":1740284230,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts.In this article, we are going to take a look at where Novartis AG  stands against the other pharmaceutical stocks.The Evolving Landscape of Healthcare and Biopharma Innovation. The possibility for additional participants to enter the field is growing along with the possible applications of GLP-1s. For example, the Swiss business Roche entered the weight-loss drug sweepstakes in 2023 when it paid up to $3.1 billion to acquire California-based Carmot Therapeutics. The corporation wants to \"fast-track\" its anti-obesity medicines to regain faith in its pipeline and take a share of the weight-loss market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-ag-nvs-among-cheap-041710477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXN33.USD","IE00B2B36J28.USD","CAGR","IE00BJT1NW94.SGD","BK4159","AG","IE00BFTCPJ56.SGD","IE00BMPRXQ63.HKD","BK4210","IE00BMPRXR70.SGD","BK4007","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4578","LU0211331839.USD","LU0348723411.USD","IE0002141913.USD","BK4609","BK4532","BK4585","BK4588","IE0009355771.USD","BK4543","BK4141","NVS"],"gpt_icon":1},{"id":"2513119162","title":"BofA moves to No Rating on Bluebird Bio after deal announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2513119162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513119162?lang=en_us&edition=fundamental","pubTime":"2025-02-22 03:20","pubTimestamp":1740165610,"startTime":"0","endTime":"0","summary":"BofA moved to No Rating on Bluebird Bio (BLUE) after the company announced it has entered a definitive merger agreement under which Carlyle and SK ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bofa-moves-to-no-rating-on-bluebird-bio-after-deal-announcement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bofa-moves-to-no-rating-on-bluebird-bio-after-deal-announcement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLUE","BK4578","BK4556"],"gpt_icon":0},{"id":"2513221677","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2513221677","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513221677?lang=en_us&edition=fundamental","pubTime":"2025-02-22 02:50","pubTimestamp":1740163822,"startTime":"0","endTime":"0","summary":"Bluebird Bio  said Friday it agreed to be acquired by Carlyle Group  managed funds and SK Capital Partners.Under the terms of the deal, bluebird shareholders will receive $3.00 per share in cash and a contingent value of $6.84 per share, payable in cash if bluebird's current product portfolio earns $600 million in net sales in any trailing 12-month period before or ending on Dec. 31, 2027.Shares slumped 41% following a surge in intraday trading volume to over 4.5 million from a daily average of about 392,000.AXT  reported a wider Q4 non-GAAP loss late Thursday compared with a year ago and sequentially. Wedbush adjusted AXT's price target to $4.50 from $5.50 while maintaining its outperform rating.Shares of AXT sank 31%, with intraday trading volume catapulting to over 5.3 million versus a daily average of about 361,000.Akamai Technologies  has \"limited\" short-term growth opportunities, BofA Securities said in a note Friday, following the company's Q4 results overnight. BofA downgraded ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IE00B64PRP62.GBP","BK4135","AXTI","BK4147","BK4578","BLUE","CG","IE00B3QW5Z07.USD","BK4585","LU2286300806.USD","IE00BGHQF748.EUR","BK4608","AKAM","BK4556","BK4139","BK4116","BK4554"],"gpt_icon":0},{"id":"2513321824","title":"Bluebird bio's CVR Payout Seen as a Stretch -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2513321824","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513321824?lang=en_us&edition=fundamental","pubTime":"2025-02-22 01:24","pubTimestamp":1740158640,"startTime":"0","endTime":"0","summary":"1224 ET - Bluebird bio's deal to be taken private will leave investors with a rich reward or a steep haircut, depending on sales of the company's gene therapies over the next three years. Analysts at William Blair think it will be the latter. Bluebird holders will get an initial $3 a share, 57% below Thursday's closing price, but contingent value rights that would be triggered by 12-month sales of $600 million would bring another $6.84 a share, for a 40% premium. William Blair says it currently models bluebird's sales reaching only $546.4 million in 2027, making the probability of achieving the CVR contingency low. Bluebird slide 39% to $4.29. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BLUE","BK4139","BK4556","CVR","BK4578"],"gpt_icon":0},{"id":"2513299576","title":"Bluebird Bio trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2513299576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513299576?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:40","pubTimestamp":1740148857,"startTime":"0","endTime":"0","summary":"09:37 EST Bluebird Bio (BLUE) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bluebird-bio-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bluebird-bio-trading-resumes-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4578","BK4556","BLUE","BK4139"],"gpt_icon":0},{"id":"2513037295","title":"Bluebird Bio trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2513037295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513037295?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:36","pubTimestamp":1740148563,"startTime":"0","endTime":"0","summary":"09:32 EST Bluebird Bio (BLUE) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bluebird-bio-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bluebird-bio-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLUE","BK4556","BK4139","BK4578"],"gpt_icon":0},{"id":"2513029577","title":"Bluebird Bio downgraded to Neutral from Outperform at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2513029577","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513029577?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:25","pubTimestamp":1740147918,"startTime":"0","endTime":"0","summary":"Baird analyst Jack Allen downgraded Bluebird Bio (BLUE) to Neutral from Outperform with a price target of $5, down from $54, after the company ente...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bluebird-bio-downgraded-to-neutral-from-outperform-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bluebird-bio-downgraded-to-neutral-from-outperform-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4578","BK4139","BLUE"],"gpt_icon":0},{"id":"2513931662","title":"BRIEF-Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513931662","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513931662?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:12","pubTimestamp":1740147171,"startTime":"0","endTime":"0","summary":"BRIEF-Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK CapitalFeb 21 (Reuters) - bluebird bio Inc BLUE.O:BLUEBIRD BIO ANNOUNCES DEFINITIVE AGREEMENT TO BE ACQUIRED BY CARLY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nTUA8F6XRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BLUE","CG","BK4135","BK4139","BK4556","BK4578","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2513729507","title":"What's Going On With Gene Therapy Company Bluebird Bio Stock Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729507","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513729507?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:53","pubTimestamp":1740146017,"startTime":"0","endTime":"0","summary":"Bluebird Bio, Inc. , on Friday, entered into a definitive agreement to be acquired by global investment firms Carlyle Group Inc.  and SK Capital Partners.The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share in cash, along with a contingent value right, which could potentially bring the total payout to up to $9.84 per share, depending on the product portfolio performance.Following the acquisition’s completion, former Mirati Therapeutics CEO David Meek is expected to take over as Bluebird Bio’s new CEO.This strategic acquisition comes after Bluebird Bio’s financial struggles, including the denial of a priority review voucher by the FDA and mounting challenges that could have led to a loan default.This strategic acquisition comes after Bluebird Bio’s challenges, including the denial of a priority review voucher by the FDA and mounting financialissues that could have led to a loan default.Also Read: Apple’s Visual Int","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/whats-going-gene-therapy-company-135337993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CG","BK4556","BK4578","BLUE","BK4135","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139"],"gpt_icon":1},{"id":"2513226066","title":"BUZZ-Bluebird bio falls on discounted take private deal with Carlyle, SK Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513226066","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513226066?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:22","pubTimestamp":1740144136,"startTime":"0","endTime":"0","summary":"BUZZ-Bluebird bio falls on discounted take private deal with Carlyle, SK Capital** Shares of gene therapy maker bluebird bio BLUE.O fall 38.6% to $4.32 premarket** Co says it would be taken private by Carlyle CG.O and SK Capital Partners** BLUE stockholders will receive $3/shr in cash, implying an equity value of around $29.2 mln** The offer is at an over 57% discount from the stock's last close of $7.04** Investment firms have also offered additional $6.84/shr, contingent upon achieving certain sales milestones, which represents a payment of about $66.5 mln** BLUE fell 69.8% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3N3PC14P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","IE00BGHQF748.EUR","BK4139","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4556","BLUE","BK4578","CG"],"gpt_icon":0},{"id":"2513267372","title":"bluebird bio Shares Down 40% Premarket; Co to Be Acquired by Carlyle and SK Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513267372","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513267372?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:02","pubTimestamp":1740142956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nL3N3PC13P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BLUE","BK4578","BK4556"],"gpt_icon":0},{"id":"2513670332","title":"Bluebird bio to Be Acquired by Carlyle Group, SK Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513670332","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513670332?lang=en_us&edition=fundamental","pubTime":"2025-02-21 20:59","pubTimestamp":1740142740,"startTime":"0","endTime":"0","summary":"Bluebird bio has struck a deal to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.Bluebird on Friday said its investors will receive an initial $3 a share in cash under the deal, along with contingent value rights worth $6.84 a share that would be triggered if the gene-therapy company's current product portfolio achieves $600 million in sales in any trailing 12-month period by the end of 2027.The potential total value of up to $9.84 a share represents a nearly 40% premium to Thursday's closing price of $7.04 for the Somerville, Mass., company.The deal is slated to close in the first half of the year.Trading in shares of bluebird was halted premarket on Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4135","BK4578","CG","IE00BGHQF748.EUR","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BLUE"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":3,"totalSize":56}]}}